PDF herunterladen
Semin intervent Radiol 2023; 40(03): 262-268
DOI: 10.1055/s-0043-1769770
Review Article

Hepatic Encephalopathy following Transjugular Intrahepatic Portosystemic Shunt Placement

Bartley Thornburg
1   Department of Radiology, Section of Interventional Radiology, Northwestern Memorial Hospital, Chicago, Illinois
› Institutsangaben
› Weitere Informationen
Auch verfügbar auf
    Lizenzen und Reprints

Abstract

Hepatic encephalopathy (HE) is a complex condition that arises as a complication of chronic liver disease and portosystemic shunting. Its pathophysiology involves several factors, including impaired ammonia metabolism, portosystemic shunting, sarcopenia, and systemic inflammation. The symptoms of HE can vary significantly, with manifestations ranging from subclinical signs to a comatose state. The West Haven classification system is most commonly used to grade the severity of HE. There is a broad differential for the presenting symptomatology of HE and other causes of altered mental status must be excluded during the workup. HE is a well-known complication of transjugular intrahepatic portosystemic shunt (TIPS) placement. Even though newer stent designs help reduce the risk of HE with smaller diameter shunts, it is essential that patients are counseled regarding this potential risk prior to the procedure. Once a diagnosis of HE has been confirmed, the mainstay of therapy is lactulose and rifaximin. In cases where a patient has received a TIPS placement and continues to experience refractory HE despite medical therapy, it may be necessary to consider shunt reduction or closure.

Keywords

TIPS - hepatic encephalopathy - cirrhosis


Publikationsverlauf

Artikel online veröffentlicht:
20. Juli 2023

© 2023. Thieme. All rights reserved.

Thieme Medical Publishers, Inc.
333 Seventh Avenue, 18th Floor, New York, NY 10001, USA

 

  • References

  • 1 D'Amico G, Morabito A, Pagliaro L, Marubini E. Survival and prognostic indicators in compensated and decompensated cirrhosis. Dig Dis Sci 1986; 31 (05) 468-475
    CrossrefPubMedGoogle Scholar
  • 2 Stepanova M, Mishra A, Venkatesan C, Younossi ZM. In-hospital mortality and economic burden associated with hepatic encephalopathy in the United States from 2005 to 2009. Clin Gastroenterol Hepatol 2012; 10 (09) 1034-41.e1
    CrossrefPubMedGoogle Scholar
  • 3 Poordad FF. Review article: the burden of hepatic encephalopathy. Aliment Pharmacol Ther 2007; 25 (Suppl. 01) 3-9
    CrossrefPubMedGoogle Scholar
  • 4 Tandon P, Ney M, Irwin I. et al. Severe muscle depletion in patients on the liver transplant wait list: its prevalence and independent prognostic value. Liver Transpl 2012; 18 (10) 1209-1216
    CrossrefPubMedGoogle Scholar
  • 5 Montano-Loza AJ, Meza-Junco J, Prado CM. et al. Muscle wasting is associated with mortality in patients with cirrhosis. Clin Gastroenterol Hepatol 2012; 10 (02) 166-173 , 173.e1
    CrossrefPubMedGoogle Scholar
  • 6 Tapper EB, Jiang ZG, Patwardhan VR. Refining the ammonia hypothesis: a physiology-driven approach to the treatment of hepatic encephalopathy. Mayo Clin Proc 2015; 90 (05) 646-658
    CrossrefPubMedGoogle Scholar
  • 7 Rose CF, Amodio P, Bajaj JS. et al. Hepatic encephalopathy: novel insights into classification, pathophysiology and therapy. J Hepatol 2020; 73 (06) 1526-1547
    CrossrefPubMedGoogle Scholar
  • 8 Dam G, Ott P, Aagaard NK, Vilstrup H. Branched-chain amino acids and muscle ammonia detoxification in cirrhosis. Metab Brain Dis 2013; 28 (02) 217-220
    CrossrefPubMedGoogle Scholar
  • 9 Wijdicks EF. Hepatic encephalopathy. N Engl J Med 2016; 375 (17) 1660-1670
    CrossrefPubMedGoogle Scholar
  • 10 Ridlon JM, Alves JM, Hylemon PB, Bajaj JS. Cirrhosis, bile acids and gut microbiota: unraveling a complex relationship. Gut Microbes 2013; 4 (05) 382-387
    CrossrefPubMedGoogle Scholar
  • 11 Kakiyama G, Pandak WM, Gillevet PM. et al. Modulation of the fecal bile acid profile by gut microbiota in cirrhosis. J Hepatol 2013; 58 (05) 949-955
    CrossrefPubMedGoogle Scholar
  • 12 McCrea M, Cordoba J, Vessey G, Blei AT, Randolph C. Neuropsychological characterization and detection of subclinical hepatic encephalopathy. Arch Neurol 1996; 53 (08) 758-763
    CrossrefPubMedGoogle Scholar
  • 13 Amodio P, Montagnese S, Gatta A, Morgan MY. Characteristics of minimal hepatic encephalopathy. Metab Brain Dis 2004; 19 (3-4): 253-267
    CrossrefPubMedGoogle Scholar
  • 14 Wiltfang J, Nolte W, Weissenborn K, Kornhuber J, Rüther E. Psychiatric aspects of portal-systemic encephalopathy. Metab Brain Dis 1998; 13 (04) 379-389
    CrossrefPubMedGoogle Scholar
  • 15 Montagnese S, De Pittà C, De Rui M. et al. Sleep-wake abnormalities in patients with cirrhosis. Hepatology 2014; 59 (02) 705-712
    CrossrefPubMedGoogle Scholar
  • 16 Weissenborn K. Diagnosis of encephalopathy. Digestion 1998; 59 (Suppl. 02) 22-24
    CrossrefPubMedGoogle Scholar
  • 17 Ferenci P, Lockwood A, Mullen K, Tarter R, Weissenborn K, Blei AT. Hepatic encephalopathy – definition, nomenclature, diagnosis, and quantification: final report of the working party at the 11th World Congresses of Gastroenterology, Vienna, 1998. Hepatology 2002; 35 (03) 716-721
    CrossrefPubMedGoogle Scholar
  • 18 Bajaj JS, Wade JB, Sanyal AJ. Spectrum of neurocognitive impairment in cirrhosis: Implications for the assessment of hepatic encephalopathy. Hepatology 2009; 50 (06) 2014-2021
    CrossrefPubMedGoogle Scholar
  • 19 Vilstrup H, Amodio P, Bajaj J. et al. Hepatic encephalopathy in chronic liver disease: 2014 Practice Guideline by the American Association for the Study of Liver Diseases and the European Association for the Study of the Liver. Hepatology 2014; 60 (02) 715-735
    CrossrefPubMedGoogle Scholar
  • 20 Bajaj JS, Pinkerton SD, Sanyal AJ, Heuman DM. Diagnosis and treatment of minimal hepatic encephalopathy to prevent motor vehicle accidents: a cost-effectiveness analysis. Hepatology 2012; 55 (04) 1164-1171
    CrossrefPubMedGoogle Scholar
  • 21 Weissenborn K, Ennen JC, Schomerus H, Rückert N, Hecker H. Neuropsychological characterization of hepatic encephalopathy. J Hepatol 2001; 34 (05) 768-773
    CrossrefPubMedGoogle Scholar
  • 22 Bajaj JS, Hafeezullah M, Franco J. et al. Inhibitory control test for the diagnosis of minimal hepatic encephalopathy. Gastroenterology 2008; 135 (05) 1591-1600.e1
    CrossrefPubMedGoogle Scholar
  • 23 Romero-Gómez M, Córdoba J, Jover R. et al. Value of the critical flicker frequency in patients with minimal hepatic encephalopathy. Hepatology 2007; 45 (04) 879-885
    CrossrefPubMedGoogle Scholar
  • 24 Lauridsen MM, Thiele M, Kimer N, Vilstrup H. The continuous reaction times method for diagnosing, grading, and monitoring minimal/covert hepatic encephalopathy. Metab Brain Dis 2013; 28 (02) 231-234
    CrossrefPubMedGoogle Scholar
  • 25 Bajaj JS, Thacker LR, Heuman DM. et al. The Stroop smartphone application is a short and valid method to screen for minimal hepatic encephalopathy. Hepatology 2013; 58 (03) 1122-1132
    CrossrefPubMedGoogle Scholar
  • 26 Amodio P, Del Piccolo F, Marchetti P. et al. Clinical features and survival of cirrhotic patients with subclinical cognitive alterations detected by the number connection test and computerized psychometric tests. Hepatology 1999; 29 (06) 1662-1667
    CrossrefPubMedGoogle Scholar
  • 27 Lockwood AH. Blood ammonia levels and hepatic encephalopathy. Metab Brain Dis 2004; 19 (3-4): 345-349
    CrossrefPubMedGoogle Scholar
  • 28 Grønbaek H, Johnsen SP, Jepsen P. et al. Liver cirrhosis, other liver diseases, and risk of hospitalisation for intracerebral haemorrhage: a Danish population-based case-control study. BMC Gastroenterol 2008; 8: 16
    CrossrefPubMedGoogle Scholar
  • 29 Bajaj JS. Management options for minimal hepatic encephalopathy. Expert Rev Gastroenterol Hepatol 2008; 2 (06) 785-790
    CrossrefPubMedGoogle Scholar
  • 30 Sharma P, Sharma BC, Puri V, Sarin SK. Critical flicker frequency: diagnostic tool for minimal hepatic encephalopathy. J Hepatol 2007; 47 (01) 67-73
    CrossrefPubMedGoogle Scholar
  • 31 Schomerus H, Hamster W. Quality of life in cirrhotics with minimal hepatic encephalopathy. Metab Brain Dis 2001; 16 (1-2): 37-41
    CrossrefPubMedGoogle Scholar
  • 32 Saxena N, Bhatia M, Joshi YK, Garg PK, Tandon RK. Auditory P300 event-related potentials and number connection test for evaluation of subclinical hepatic encephalopathy in patients with cirrhosis of the liver: a follow-up study. J Gastroenterol Hepatol 2001; 16 (03) 322-327
    CrossrefPubMedGoogle Scholar
  • 33 Groeneweg M, Moerland W, Quero JC, Hop WC, Krabbe PF, Schalm SW. Screening of subclinical hepatic encephalopathy. J Hepatol 2000; 32 (05) 748-753
    CrossrefPubMedGoogle Scholar
  • 34 Saunders JB, Walters JR, Davies AP, Paton A. A 20-year prospective study of cirrhosis. Br Med J (Clin Res Ed) 1981; 282 (6260): 263-266
    CrossrefPubMedGoogle Scholar
  • 35 Romero-Gómez M, Boza F, García-Valdecasas MS, García E, Aguilar-Reina J. Subclinical hepatic encephalopathy predicts the development of overt hepatic encephalopathy. Am J Gastroenterol 2001; 96 (09) 2718-2723
    CrossrefPubMedGoogle Scholar
  • 36 Jepsen P, Ott P, Andersen PK, Sørensen HT, Vilstrup H. Clinical course of alcoholic liver cirrhosis: a Danish population-based cohort study. Hepatology 2010; 51 (05) 1675-1682
    CrossrefPubMedGoogle Scholar
  • 37 Coltorti M, Del Vecchio-Blanco C, Caporaso N, Gallo C, Castellano L. National Project on Liver Cirrhosis Group. Liver cirrhosis in Italy: a multicentre study on presenting modalities and the impact on health care resources. Ital J Gastroenterol 1991; 23 (01) 42-48
    PubMedGoogle Scholar
  • 38 Watson H, Jepsen P, Wong F, Ginès P, Córdoba J, Vilstrup H. Satavaptan treatment for ascites in patients with cirrhosis: a meta-analysis of effect on hepatic encephalopathy development. Metab Brain Dis 2013; 28 (02) 301-305
    CrossrefPubMedGoogle Scholar
  • 39 Benvegnù L, Gios M, Boccato S, Alberti A. Natural history of compensated viral cirrhosis: a prospective study on the incidence and hierarchy of major complications. Gut 2004; 53 (05) 744-749
    CrossrefPubMedGoogle Scholar
  • 40 Hartmann IJ, Groeneweg M, Quero JC. et al. The prognostic significance of subclinical hepatic encephalopathy. Am J Gastroenterol 2000; 95 (08) 2029-2034
    CrossrefPubMedGoogle Scholar
  • 41 Bustamante J, Rimola A, Ventura PJ. et al. Prognostic significance of hepatic encephalopathy in patients with cirrhosis. J Hepatol 1999; 30 (05) 890-895
    CrossrefPubMedGoogle Scholar
  • 42 Sharma BC, Sharma P, Agrawal A, Sarin SK. Secondary prophylaxis of hepatic encephalopathy: an open-label randomized controlled trial of lactulose versus placebo. Gastroenterology 2009; 137 (03) 885-891 , 891.e1
    CrossrefPubMedGoogle Scholar
  • 43 Nolte W, Wiltfang J, Schindler C. et al. Portosystemic hepatic encephalopathy after transjugular intrahepatic portosystemic shunt in patients with cirrhosis: clinical, laboratory, psychometric, and electroencephalographic investigations. Hepatology 1998; 28 (05) 1215-1225
    CrossrefPubMedGoogle Scholar
  • 44 Papatheodoridis GV, Goulis J, Leandro G, Patch D, Burroughs AK. Transjugular intrahepatic portosystemic shunt compared with endoscopic treatment for prevention of variceal rebleeding: a meta-analysis. Hepatology 1999; 30 (03) 612-622
    CrossrefPubMedGoogle Scholar
  • 45 Bureau C, Garcia-Pagan JC, Otal P. et al. Improved clinical outcome using polytetrafluoroethylene-coated stents for TIPS: results of a randomized study. Gastroenterology 2004; 126 (02) 469-475
    CrossrefPubMedGoogle Scholar
  • 46 Masson S, Mardini HA, Rose JD, Record CO. Hepatic encephalopathy after transjugular intrahepatic portosystemic shunt insertion: a decade of experience. QJM 2008; 101 (06) 493-501
    CrossrefPubMedGoogle Scholar
  • 47 Yang Z, Han G, Wu Q. et al. Patency and clinical outcomes of transjugular intrahepatic portosystemic shunt with polytetrafluoroethylene-covered stents versus bare stents: a meta-analysis. J Gastroenterol Hepatol 2010; 25 (11) 1718-1725
    CrossrefPubMedGoogle Scholar
  • 48 Bureau C, Thabut D, Oberti F. et al. Transjugular intrahepatic portosystemic shunts with covered stents increase transplant-free survival of patients with cirrhosis and recurrent ascites. Gastroenterology 2017; 152 (01) 157-163
    CrossrefPubMedGoogle Scholar
  • 49 Lv Y, Yang Z, Liu L. et al; AVB-TIPS Study Group. Early TIPS with covered stents versus standard treatment for acute variceal bleeding in patients with advanced cirrhosis: a randomised controlled trial. Lancet Gastroenterol Hepatol 2019; 4 (08) 587-598
    CrossrefPubMedGoogle Scholar
  • 50 García-Pagán JC, Caca K, Bureau C. et al; Early TIPS (Transjugular Intrahepatic Portosystemic Shunt) Cooperative Study Group. Early use of TIPS in patients with cirrhosis and variceal bleeding. N Engl J Med 2010; 362 (25) 2370-2379
    CrossrefPubMedGoogle Scholar
  • 51 Garcia-Pagán JC, Di Pascoli M, Caca K. et al. Use of early-TIPS for high-risk variceal bleeding: results of a post-RCT surveillance study. J Hepatol 2013; 58 (01) 45-50
    CrossrefPubMedGoogle Scholar
  • 52 Bai M, Qi X, Yang Z. et al. Predictors of hepatic encephalopathy after transjugular intrahepatic portosystemic shunt in cirrhotic patients: a systematic review. J Gastroenterol Hepatol 2011; 26 (06) 943-951
    CrossrefPubMedGoogle Scholar
  • 53 Casadaban LC, Parvinian A, Minocha J. et al. Clearing the confusion over hepatic encephalopathy after TIPS creation: incidence, prognostic factors, and clinical outcomes. Dig Dis Sci 2015; 60 (04) 1059-1066
    CrossrefPubMedGoogle Scholar
  • 54 Riggio O, Angeloni S, Salvatori FM. et al. Incidence, natural history, and risk factors of hepatic encephalopathy after transjugular intrahepatic portosystemic shunt with polytetrafluoroethylene-covered stent grafts. Am J Gastroenterol 2008; 103 (11) 2738-2746
    CrossrefPubMedGoogle Scholar
  • 55 Nardelli S, Lattanzi B, Torrisi S. et al. Sarcopenia is risk factor for development of hepatic encephalopathy after transjugular intrahepatic portosystemic shunt placement. Clin Gastroenterol Hepatol 2017; 15 (06) 934-936
    CrossrefPubMedGoogle Scholar
  • 56 Praktiknjo M, Clees C, Pigliacelli A. et al. Sarcopenia is associated with development of acute-on-chronic liver failure in decompensated liver cirrhosis receiving transjugular intrahepatic portosystemic shunt. Clin Transl Gastroenterol 2019; 10 (04) e00025-e00025
    CrossrefPubMedGoogle Scholar
  • 57 Berlioux P, Robic MA, Poirson H. et al. Pre-transjugular intrahepatic portosystemic shunts (TIPS) prediction of post-TIPS overt hepatic encephalopathy: the critical flicker frequency is more accurate than psychometric tests. Hepatology 2014; 59 (02) 622-629
    CrossrefPubMedGoogle Scholar
  • 58 Nardelli S, Gioia S, Pasquale C. et al. Cognitive impairment predicts the occurrence of hepatic encephalopathy after transjugular intrahepatic portosystemic shunt. Am J Gastroenterol 2016; 111 (04) 523-528
    CrossrefPubMedGoogle Scholar
  • 59 Chung HH, Razavi MK, Sze DY. et al. Portosystemic pressure gradient during transjugular intrahepatic portosystemic shunt with Viatorr stent graft: what is the critical low threshold to avoid medically uncontrolled low pressure gradient related complications?. J Gastroenterol Hepatol 2008; 23 (01) 95-101
    CrossrefPubMedGoogle Scholar
  • 60 Miraglia R, Maruzzelli L, Di Piazza A. et al. Transjugular intrahepatic portosystemic shunt using the new Gore Viatorr controlled expansion endoprosthesis: prospective, single-center, preliminary experience. Cardiovasc Intervent Radiol 2019; 42 (01) 78-86
    CrossrefPubMedGoogle Scholar
  • 61 Boike JR, Thornburg BG, Asrani SK. et al; Advancing Liver Therapeutic Approaches (ALTA) Consortium. North American practice-based recommendations for transjugular intrahepatic portosystemic shunts in portal hypertension. Clin Gastroenterol Hepatol 2022; 20 (08) 1636-1662.e36
    CrossrefPubMedGoogle Scholar
  • 62 Luo X, Wang X, Zhu Y. et al. Clinical efficacy of transjugular intrahepatic portosystemic shunt created with expanded polytetrafluoroethylene-covered stent-grafts: 8-mm versus 10-mm. Cardiovasc Intervent Radiol 2019; 42 (05) 737-743
    CrossrefPubMedGoogle Scholar
  • 63 Schepis F, Vizzutti F, Garcia-Tsao G. et al. Under-dilated TIPS associate with efficacy and reduced encephalopathy in a prospective, non-randomized study of patients with cirrhosis. Clin Gastroenterol Hepatol 2018; 16 (07) 1153-1162.e7
    CrossrefPubMedGoogle Scholar
  • 64 Wang Q, Lv Y, Bai M. et al. Eight millimetre covered TIPS does not compromise shunt function but reduces hepatic encephalopathy in preventing variceal rebleeding. J Hepatol 2017; 67 (03) 508-516
    CrossrefPubMedGoogle Scholar
  • 65 Sauerbruch T, Mengel M, Dollinger M. et al; German Study Group for Prophylaxis of Variceal Rebleeding. Prevention of rebleeding from esophageal varices in patients with cirrhosis receiving small-diameter stents versus hemodynamically controlled medical therapy. Gastroenterology 2015; 149 (03) 660-668.e1
    CrossrefPubMedGoogle Scholar
  • 66 Strauss E, Tramote R, Silva EP. et al. Double-blind randomized clinical trial comparing neomycin and placebo in the treatment of exogenous hepatic encephalopathy. Hepatogastroenterology 1992; 39 (06) 542-545
    PubMedGoogle Scholar
  • 67 Als-Nielsen B, Gluud LL, Gluud C. Non-absorbable disaccharides for hepatic encephalopathy: systematic review of randomised trials. BMJ 2004; 328 (7447): 1046
    CrossrefPubMedGoogle Scholar
  • 68 Bass NM, Mullen KD, Sanyal A. et al. Rifaximin treatment in hepatic encephalopathy. N Engl J Med 2010; 362 (12) 1071-1081
    CrossrefPubMedGoogle Scholar
  • 69 Huang E, Esrailian E, Spiegel BM. The cost-effectiveness and budget impact of competing therapies in hepatic encephalopathy - a decision analysis. Aliment Pharmacol Ther 2007; 26 (08) 1147-1161
    CrossrefPubMedGoogle Scholar
  • 70 Riggio O, Nardelli S, Moscucci F, Pasquale C, Ridola L, Merli M. Hepatic encephalopathy after transjugular intrahepatic portosystemic shunt. Clin Liver Dis 2012; 16 (01) 133-146
    CrossrefPubMedGoogle Scholar
  • 71 Fanelli F, Salvatori FM, Rabuffi P. et al. Management of refractory hepatic encephalopathy after insertion of TIPS: long-term results of shunt reduction with hourglass-shaped balloon-expandable stent-graft. AJR Am J Roentgenol 2009; 193 (06) 1696-1702
    CrossrefPubMedGoogle Scholar
  • 72 Cookson DT, Zaman Z, Gordon-Smith J, Ireland HM, Hayes PC. Management of transjugular intrahepatic portosystemic shunt (TIPS)-associated refractory hepatic encephalopathy by shunt reduction using the parallel technique: outcomes of a retrospective case series. Cardiovasc Intervent Radiol 2011; 34 (01) 92-99
    CrossrefPubMedGoogle Scholar
  • 73 Kochar N, Tripathi D, Ireland H, Redhead DN, Hayes PC. Transjugular intrahepatic portosystemic stent shunt (TIPSS) modification in the management of post-TIPSS refractory hepatic encephalopathy. Gut 2006; 55 (11) 1617-1623
    CrossrefPubMedGoogle Scholar
  • 74 Maleux G, Heye S, Verslype C, Nevens F. Management of transjugular intrahepatic portosystemic shunt induced refractory hepatic encephalopathy with the parallel technique: results of a clinical follow-up study. J Vasc Interv Radiol 2007; 18 (08) 986-992 , quiz 993
    CrossrefPubMedGoogle Scholar
  • 75 Maleux G, Verslype C, Heye S, Wilms G, Marchal G, Nevens F. Endovascular shunt reduction in the management of transjugular portosystemic shunt-induced hepatic encephalopathy: preliminary experience with reduction stents and stent-grafts. AJR Am J Roentgenol 2007; 188 (03) 659-664
    CrossrefPubMedGoogle Scholar